Member access

4-Traders Homepage  >  Shares  >  Amex  >  CEL-SCI Corporation       US1508374097

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.The company's lead investigational therapy, Multikine, is being developed as a potential therapeutic agent... 
More about the company
Financials ($)
Sales 2014 0,23 M
EBIT 2014 -25,2 M
Net income 2014 -
Debt 2014 -
Yield 2014 -
Sales 2015 0,26 M
EBIT 2015 -26,9 M
Net income 2015 -
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 235x
Capi. / Sales 2015 209x
Capitalization 54,3 M
More Financials
Latest news on CEL-SCI CORPORATION
11/06 CEL SCI : Enlists 22 Patients During October in Phase III Immunotherapy Head and..
11/05 CEL SCI : Announces Closing of Public Offering for Gross Proceeds of $6 Million
11/05 CEL SCI : Updates on Closing of Public Offering for Gross Proceeds
11/03 CEL SCI : NEW STORY CEL-SCI Enrolls 22 Patients during October in Its Phase III ..
11/03 CEL SCI : Enrolls 22 Patients During October in Its Phase III Immunotherapy Head..
11/02 CEL SCI : NEW STORY CEL-SCI Corporation Announces Closing of Public Offering for..
10/31 CEL SCI : Concludes Public Offering for Gross Proceeds of $6 Million
10/29 CEL SCI : Announces Proposed Public Offering of Common Stock and Warrants
10/29 CEL SCI : to Raise $1 Million in Registered Direct Offering
10/29 CEL SCI : Prices $6 Million Public Offering of Common Stock and Warrants
10/29 CEL SCI : Closes Public Offering of Common Stock Shares
10/29 CEL SCI : Reports Closing of Public Offering for Gross Proceeds
More news
Comments 
Advertisement
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF